One Case of Cesarean Scar Pregnancy with Severe Aphthous Ulcer and Ⅲ Degree Myelosuppression Induced by Methotrexate

doi:10.19803/j.1672-8629.2021.01.18

Abstract

Abstract: Objective To provide reference for more rational clinical use of methotrexate in order to reduce adverse drug reaction(ADR) and treatment methods after ADR.Methods Clinical pharmacists participated in a case for cesarean scar pregnancy with severe aphthous ulcer and III degree myelosuppression caused by methotrexate chemotherapy ,analyzed the ADR causes,prevention and cure,and pharmaceutical care.Results The ADR of methotrexate can be avoided or alleviated through the detection of MTHFR genotype in patients and preventive measures in advance.Conclusion The participation of clinical pharmacists in the treatment of patients can provide pharmaceutical care and medication education for patients,improve the level of clinical treatment,and provide more safe,effective,economical and reasonable pharmaceutical care for patients.

Key words: methotrexate, aphthous ulcer, myelosuppression, clinical pharmacist, pharmaceutical care

CLC Number:

R969.3

HE Shouyun, WU Yingqi. One Case of Cesarean Scar Pregnancy with Severe Aphthous Ulcer and Ⅲ Degree Myelosuppression Induced by Methotrexate[J]. Chinese Journal of Pharmacovigilance, 2021, 18(1): 87-89.

References

[1] Xie X,Sun BH,Duan T.Obstetrics and Gynecology (妇产科学)[M].Beijing:People's Medical Publishing House:2018:80-81.
[2] Family Planning Group of Gynecology and Obstetrics Branch in Chinese Medical Association.Expert consensus on diagnosis and treatment of scar pregnancy after cesarean section (2016)[J].Clinical Education of General Practice(全科医学临床与教育),2016,51(8):5-9.
[3] Yang YW,Dong D,Song F.Retrospective analysis of 34 cases of adverse reactions induced by methotrexate[J].Chinese Journal of Pharmacovigilance(中国药物警戒),2014,11(9):557-560.
[4] Wei XN,Liang JJ,Ma JD,et al.Clinical characteristics and risk factors of low-dose methotrexate-induced myelosuppression[J].Journal of New Medicine(新医学),2019,50(3):174-178.
[5] Kivity S,Zafrir Y,Loebstein R,et al.Clinical characteristics and risk factors for low dose methotrexate toxicity:A cohort of 28 patients[J].Autoimmunity Reviews,2014,13(11):1109-1113.
[6] Wang YR,Wang J,An LN,et al.Analysis of influence factors of the common adverse reactions after high-dose methotrexate chemotherapy[J].The Chinese Journal of Clinical Pharmacology(中国临床药理学杂志),2016,32(2):138-140.
[7] Zhou XK,Shu WY,Liang M,et al.Association of Genetic Polymo-rphisms of MTHFR and Methotrexate-related Adverse Reaction[J].Chinese Journal of Pharmacovigilance(中国药物警戒),2013,10(11):647-649.
[8] Xiang Y,Zhou Q,Wu XH,et al.Guidelines for diagnosis and treatment of gestational trophoblast disease[J].Chinese Journal of Practical Gynecology and Obstetrics(中国实用妇科与产科杂志),2018,34(9):46-53.
[9] Chen YJ,Lin J,Zhou J,et al.The Guidance of the Plasma Concentration of Methotrexate for Calcium Folinate Treatment[J].Chinese Journal of New Drugs and Clinical Remedies(中国新药与临床志),2005,24(2):134-135.
[10] Oosterom N,Dirks NF,Heil SG,et al.A decrease in vitamin D levels is associated with methotrexate-induced oral mucositis in children with acute lymphoblastic leukemia[J].Supportive Care Cancer,2018,27(14):1-8.
[11] Zhang Y,Li L,Miao RN.Effects of different concentrations of sodium bicarbonate gargle on patients with oral ulcer caused by myelosuppression after chemotherapy for acute leukemia[J].Journal of QiLu Nursing(齐鲁护理杂志),2019,25(6):120-121.
[12] Du GZ,Li R,Yu CH.Effect of 4 ℃ Normal Saline Gargle on prevention of oral ulcer caused by methotrexate[J].Medical Equipment(医疗装备),2015,28(4):58-59.

[1]	FAN Kaikai, WANG Cong, LIU Hongfeng, WANG Xiyong. Effects of clinical pharmacist interventions on usage of alanyl-glutamine injections in a hospital [J]. Chinese Journal of Pharmacovigilance, 2024, 21(2): 181-184.
[2]	ZHANG Xialan, YUAN Jing, WU Bin, QIN Yuanyuan. Medications of apatinib mesylate in patients with malignant tumors [J]. Chinese Journal of Pharmacovigilance, 2023, 20(8): 927-932.
[3]	WANG Ran, LI Yifan, LIU Xiaoyan, FENG Xin. One case of pharmaceutical care of drug exposure during pregnancy [J]. Chinese Journal of Pharmacovigilance, 2023, 20(8): 933-934.
[4]	CHEN Jie, QIN Kan. Evaluation of individualized parenteral nutrition delivery [J]. Chinese Journal of Pharmacovigilance, 2023, 20(7): 812-816.
[5]	LIU Jing, XIA Liang, ZHANG Shijie. Pharmaceutical care of a patient with acute pancreatitis complicated with multiple drug allergy undergoing drug stimulation test [J]. Chinese Journal of Pharmacovigilance, 2023, 20(7): 822-824.
[6]	WANG Ran, FENG Xin, DU Boran. Advances in risk assessment and pharmaceutical care of pregnancy medication exposure during perinatal period [J]. Chinese Journal of Pharmacovigilance, 2023, 20(7): 836-840.
[7]	LUO Fangmei, WU Pan, LI Jing, WANG Ting, WANG Fangjie. Correlations of ABCB1 C3435T genetic polymorphism with serum concentrations and adverse reactions of high-dose methotrexate in children with mature B-cell lymphoma [J]. Chinese Journal of Pharmacovigilance, 2023, 20(6): 675-679.
[8]	HUO Peiqiong, ZHENG Peng, SU Zhenhao. Pharmacovigilance in retail pharmacies for special or major diseases [J]. Chinese Journal of Pharmacovigilance, 2023, 20(4): 428-432.
[9]	YANG Yan, ZHOU Dexi, WU Xinli, XUE Shuya, DING Haihua, ZHANG Quan, ZHANG Yunling. Eighty-four cases of adverse drug reactions caused by novel anti-tumor drugs [J]. Chinese Journal of Pharmacovigilance, 2023, 20(3): 334-338.
[10]	LIU Baohua, SHEN Aizong, SU Dan. Pharmaceutical care for a case of severe myelosuppression induced by meropenem injection combined with vancomycin injection [J]. Chinese Journal of Pharmacovigilance, 2023, 20(3): 339-342.
[11]	YAO Xin, GE Qiuge, LI Yamin, WANG Yifan, LI Yuanyuan, LIU Zhiqiang. Adverse drug reactions caused by new anti-tumor drugs from 2018 to 2022 in one hospital [J]. Chinese Journal of Pharmacovigilance, 2023, 20(11): 1273-1278.
[12]	ZHENG Jinfeng, WANG Jinghong. Pharmaceutical care of one case of malignant arrhythmia induced by multidrug combination [J]. Chinese Journal of Pharmacovigilance, 2023, 20(11): 1279-1281.
[13]	SU Su, WU Shiqi, ZHANG Qingxia, YAN Suying. Pharmaceutical care of a patient with indapamide-induced agranulocytosis [J]. Chinese Journal of Pharmacovigilance, 2023, 20(11): 1282-1285.
[14]	WANG Yanting, ZHANG Yuanyuan, CHEN Yiran, SUN Jie, ZHU Yu, YANG Liyan, WU Zhigui, SHEN Lijun, CHENG Min, LI Guohui. Balanced decision between anti-infective and antitumor therapies and pharmaceutical care for a malignant tumor patient [J]. Chinese Journal of Pharmacovigilance, 2023, 20(10): 1168-1172.
[15]	WANG Qiru, ZUO Li, DU Qiong, YE Ling, RUAN Cong, ZHAI Qing, XU Rui. Pharmaceutical care of a patient with grade Ⅳ myelosuppression induced by olapalil [J]. Chinese Journal of Pharmacovigilance, 2023, 20(10): 1176-1180.